STERIS plc
STE
Rangering i aksjer
#1070
STERIS plc provides infection prevention products and services in the United... STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
Aksjekurs
$222.31
Sist synkronisert: 2026-10-19
Markedsverdi
$21.68B
Endring (1 dag)
0.06%
Endring (1 år)
-8.22%
Land
IE
Handel STERIS plc (STE)
Kategori
Healthcare
P/E-forhold for STERIS plc (STE)
P/E-forhold per October 2026 TTM: 26.50
Ifølge STERIS plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 26.50. Ved slutten av 2024 hadde selskapet en P/E på 57.73.
P/E-forholdshistorikk for STERIS plc fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 26.50 | -27.11% |
| 2025 | 36.35 | -37.03% |
| 2024 | 57.73 | -67.60% |
| 2023 | 178.19 | 84.29% |
| 2022 | 96.69 | 136.75% |
| 2021 | 40.84 | 40.30% |
| 2020 | 29.11 | -17.88% |
| 2019 | 35.45 | 29.90% |
| 2018 | 27.29 | -49.46% |
| 2017 | 53.99 | 19.05% |
| 2016 | 45.35 | 46.71% |
| 2015 | 30.91 | 42.11% |
| 2014 | 21.75 | 45.00% |
| 2013 | 15.00 | 10.64% |
| 2012 | 13.56 | -66.07% |
| 2011 | 39.96 | 159.24% |
| 2010 | 15.41 | 24.68% |
| 2009 | 12.36 | -43.79% |
| 2008 | 21.99 | 4.33% |
| 2007 | 21.08 | -12.03% |
| 2006 | 23.96 | 17.67% |
| 2005 | 20.36 | 7.34% |
| 2004 | 18.97 | -17.33% |
| 2003 | 22.95 | -27.34% |
| 2002 | 31.58 | -95.52% |
| 2001 | 705.00 | 1,000.49% |
| 2000 | 64.06 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| - | - |
CN
|
|
| - | - |
CH
|
|
| - | - |
CH
|
|
| - | - |
CN
|
|
| 20.66 | -22.01% |
KR
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.